Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882350 | 0.78 | KCNH2 (0.52) | KCNH2CACNA1ISCN5ACACNA1HTAS1R3 | |
| SCHEMBL2881618 | 0.78 | KCNH2 (0.56) | KCNH2CACNA1ISCN5ACACNA1HTAS1R3 | |
| SCHEMBL2886622 | 0.72 | KCNH2 (0.58) | KCNH2CACNA1ISCN5ACACNA1HP2RX7 | |
| SCHEMBL2888152 | 0.72 | KCNH2 (0.63) | KCNH2CACNA1ISCN5ACACNA1HP2RX7 | |
| SCHEMBL5069097 | 0.69 | CACNA1H (0.36) | KCNH2CACNA1ISCN5ACACNA1HP2RX7 | |
| SCHEMBL5069616 | 0.63 | KCNH2 (0.38) | KCNH2CACNA1ISCN5ACACNA1HP2RX7 | |
| SCHEMBL14708790 | 0.63 | KCNH2 (0.53) | KCNH2CACNA1ISCN5ACACNA1HP2RX7 | |
| SCHEMBL2882508 | 0.62 | KCNH2 (0.52) | KCNH2CACNA1ISCN5ACACNA1H | |
| SCHEMBL2882511 | 0.62 | KCNH2 (0.52) | KCNH2CACNA1ISCN5ACACNA1H | |
| SCHEMBL2885033 | 0.62 | P2RX7 (0.57) | KCNH2CACNA1ISCN5ACACNA1HP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | KCNH2 38/4885CACNA1I 2/4885SCN5A 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.